Welcome to our dedicated page for Masimo news (Ticker: MASI), a resource for investors and traders seeking the latest updates and insights on Masimo stock.
Masimo Corporation (NASDAQ: MASI) is a global medical technology company focused on noninvasive patient monitoring, sensors, patient monitors, and automation and connectivity solutions. The Masimo news feed on Stock Titan aggregates company announcements, financial updates, clinical study results, and other material developments that the company discloses through press releases and regulatory communications.
Investors and observers can find news on Masimo e2 80 99s quarterly and annual financial results, including GAAP and non-GAAP revenue, earnings per diluted share, and constant currency revenue growth, as reported in earnings releases and related Form 8-K filings. These updates often include commentary from management on the performance of the healthcare business, operating efficiency initiatives, and guidance for future periods.
Masimo news also covers strategic and corporate actions, such as the completion of the sale of its consumer audio business, Sound United, to Harman International Industries, Incorporated, as disclosed in a September 23, 2025 Form 8-K and related press release. Additional items may include announcements about investor days, participation in healthcare conferences, and updates on long-range financial targets and growth pillars.
Given Masimo e2 80 99s emphasis on clinical evidence and intellectual property, the news flow features results from clinical and feasibility studies involving Masimo SET ae pulse oximetry, including research on performance across different skin tones and in critically ill patients. It also includes statements on significant legal outcomes, such as jury verdicts in patent infringement cases related to Masimo e2 80 99s technologies. By following this page, readers can monitor how Masimo communicates its financial performance, strategic focus on healthcare monitoring, and developments in clinical validation and intellectual property protection.
Politan Capital Management, an 8.9% shareholder of Masimo (NASDAQ: MASI), has issued a statement from its legal advisors regarding a proxy contest. The statement, made by representatives from Schulte Roth & Zabel and Munger, Tolles & Olson, expresses disagreement with a court ruling that Politan violated a sealing order. The legal teams believed that while the contents of the order were sealed, the outcome of the motion was not, and had approved Politan's press release on September 12.
Despite disagreeing with the ruling, the legal advisors noted that the court denied Masimo's efforts to prevent Politan from voting and rejected Masimo's attempt to delay the upcoming 2024 Annual Meeting of Stockholders. Politan urges shareholders to vote using the WHITE universal proxy card in support of Politan's nominees and recommendations.
Masimo (NASDAQ: MASI) has issued a statement addressing false claims made by Politan Capital Management LP and Quentin Koffey in their proxy contest. The company's lawsuit has forced Politan to issue corrective disclosures on several misleading statements, including:
1. Lies about the spin-off and the Special Committee's decision
2. False claims about the Board's role in the sale process
3. Misrepresentations about the outcome of the sale process
Masimo urges stockholders to vote 'FOR' its director nominees, Joe Kiani and Christopher Chavez, on the updated GOLD proxy card for the upcoming September 19, 2024 Annual Meeting. The company emphasizes that its recent earnings show its strategy is working and warns against risking this momentum by handing control to an inexperienced team with no clear strategy.
Politan Capital Management, an 8.9% shareholder of Masimo (NASDAQ: MASI), issued a statement regarding a California federal court ruling that denied Masimo's attempt to block Politan from voting proxies it collects. The ruling clears the way for the shareholder vote to proceed on September 19 at Masimo's 2024 Annual Meeting of Stockholders.
Politan expressed satisfaction with the court's decision, stating it removes the last barrier to shareholders electing truly independent directors to Masimo's Board. The company criticized Masimo's litigation as a desperate move to prevent a fair election. Politan also highlighted the need for independent oversight on Masimo's Board, accusing the current Board of recklessly spending shareholder resources and misleading investors.
Masimo (NASDAQ: MASI) urges stockholders to vote 'FOR' Joe Kiani and Christopher Chavez at the September 19, 2024 Annual Meeting. The company emphasizes that this vote will determine Masimo's future leadership and strategy. Key points include:
1. Masimo's current leadership has driven innovation and growth, with 22% healthcare revenue growth year-over-year.
2. The company warns that electing Politan's nominees could lead to a loss of key employees and expertise.
3. Masimo has raised its full-year EPS guidance and aims to double EPS to $8 in five years.
4. The company criticizes Politan's lack of concrete plans and medical technology expertise.
5. Masimo highlights its track record of value creation and commitment to addressing stockholder feedback.
Masimo (NASDAQ: MASI) announced that Saint-Denis Hospital Center in France is adopting the Masimo SafetyNet® cloud-based telemonitoring platform for their experimental mobile neonatology unit. This innovative project, launched in February, aims to facilitate earlier discharge of premature newborns from the ICU to home while maintaining close hospital supervision.
The system uses Masimo's Radius PPG® sensor with SET® technology, worn on the baby's foot, to send health data to a smartphone app for parents and hospital caregivers. This allows for continuous monitoring and quick response to changes in the baby's condition. The project could potentially allow premature babies to return home before the typical 36 weeks of corrected age, benefiting both families and hospital resources.
Masimo (NASDAQ: MASI) is urging stockholders to vote 'FOR' its director nominees, Joe Kiani and Christopher Chavez, at the upcoming Annual Meeting on September 19, 2024. The company has shared details from unredacted legal filings about Quentin Koffey's alleged multi-year plan to take control of Masimo. Key points include:
1. Politan raised nearly $440 million specifically targeting Masimo stock acquisition.
2. Politan allegedly failed to disclose its investors in its 13D filing.
3. Quentin Koffey, as a Masimo director, reportedly hired firms to find former employees willing to provide damaging information about the company.
4. Koffey allegedly threatened other directors and refused to sign required SEC filings.
5. Masimo claims Koffey sabotaged efforts to separate the consumer business.
Masimo argues that Koffey's actions demonstrate he is not acting in the best interests of all stockholders and warns against giving him control of the company.
Masimo (NASDAQ: MASI) has announced its participation in the Wells Fargo Healthcare Conference on September 5, 2024. The company's management will present at 10:15 a.m. Eastern Time. Investors and interested parties can access a live webcast of the presentation through Masimo's official website. For those unable to attend the live event, a replay of the webcast will be made available after the presentation concludes.
This conference provides Masimo with an opportunity to showcase its latest developments and strategies to investors and industry professionals. The company's participation in such events often signals its commitment to transparency and shareholder engagement.
Masimo (NASDAQ: MASI) and March of Dimes are partnering to support parents with babies in the Neonatal Intensive Care Unit (NICU). Masimo will donate $100,000 worth of Stork™ Smart Home Baby Monitoring Systems to families in need through March of Dimes' NICU Family Support program. The partnership aims to assist over 50,000 families nationwide as they transition from hospital to home.
Stork, an FDA-cleared monitoring system, uses Masimo SET® sensor technology to track a baby's oxygen saturation, pulse rate, and skin temperature. The collaboration will include NICU Awareness Month programs, donation matching events, and educational video releases. This initiative addresses the needs of the 9-13% of babies requiring NICU stays due to complex medical needs.
Masimo (NASDAQ: MASI) urges stockholders to vote 'FOR' its director nominees, Joe Kiani and Christopher Chavez, at the upcoming Annual Meeting on September 19, 2024. The company highlights the risks of Politan Capital Management gaining control of the Board, potentially leading to a mass exodus of critical leadership and talent. Masimo emphasizes its strong Q2 2024 performance, including:
- 22% growth in healthcare revenue year-over-year
- Record-breaking new hospital contracts
- Progress towards a 30% operating margin
- Raised full-year EPS guidance
Masimo is also evaluating a potential separation of its consumer business to maximize stockholder value. The company warns that Politan's proxy campaign could derail ongoing progress and value creation.
Masimo's Signal Extraction Technology® (SET®) pulse oximetry continues to lead the industry with superior accuracy and reliability. As of 2024, SET® is the primary pulse oximetry technology at all ten top U.S. hospitals and monitors over 200 million patients annually worldwide. With more than 100 clinical studies demonstrating its performance, SET® offers industry-best SpO2 accuracy in challenging conditions across all patient populations and skin tones.
Masimo SET® has shown significant improvements in patient outcomes, including zero preventable deaths from opioid-induced respiratory depression in a 10-year study, 80% reduction in retinopathy of prematurity, and improved screening for critical congenital heart disease. It also reduces false alarms by 86% and has led to 60% fewer rapid response team activations. Additionally, SET® contributes to environmental sustainability and cost savings for hospitals.